CAR-T Therapy can be a Useful Treatment Modality for more than Just Hematologic Malignancies DOI Open Access
Kazuhiro Ikegame

Internal Medicine, Год журнала: 2024, Номер unknown

Опубликована: Янв. 1, 2024

Chimeric antigen receptor-T-cell (CAR-T) therapy for hematologic malignancies has made significant advancements over the years, and it is now incorporated as a treatment algorithm. Early phase clinical trials are underway various solid tumors, effectiveness of CAR-T cell been demonstrated specific types glioma several tumors. However, its efficacy does not match that observed in hematological malignancies. Recently, case series reported targeting CD19 autoimmune diseases such systemic lupus erythematosus, leading to dramatic improvement symptoms possibility discontinuing immunosuppressive agents. Furthermore, expected be effective against viruses Aspergillus spp. Finally, attempts have introduce CAR constructs into regulatory T cells target their effects. This article introduces current progress beyond only discusses future directions, considering medical situation Japan.

Язык: Английский

Chimeric antigen receptor T-cell therapy in autoimmune diseases DOI Creative Commons
Jie Liu, Zhao Yan, Zhao Hai

и другие.

Frontiers in Immunology, Год журнала: 2024, Номер 15

Опубликована: Ноя. 19, 2024

The administration of T cells that have been modified to carry chimeric antigen receptors (CARs) aimed at B has an effective strategy in treating cell malignancies. This breakthrough spurred the creation CAR intended specifically reduce or alter faulty immune responses associated with autoimmune disorders. Early positive outcomes from clinical trials involving target protein CD19 patients suffering diseases driven by reported. Additional strategies are being developed broaden use therapy and enhance its safety conditions. These include employing autoantireceptors (CAAR) eliminate reactive autoantigens, using regulatory (Tregs) engineered antigen-specific CARs for precise modulation. discussion emphasizes key factors such as choosing right groups, designing constructs, defining tolerable side effects, achieving a lasting modification, all which critical safely integrating diseases.

Язык: Английский

Процитировано

1

CAR-T Therapy can be a Useful Treatment Modality for more than Just Hematologic Malignancies DOI Open Access
Kazuhiro Ikegame

Internal Medicine, Год журнала: 2024, Номер unknown

Опубликована: Янв. 1, 2024

Chimeric antigen receptor-T-cell (CAR-T) therapy for hematologic malignancies has made significant advancements over the years, and it is now incorporated as a treatment algorithm. Early phase clinical trials are underway various solid tumors, effectiveness of CAR-T cell been demonstrated specific types glioma several tumors. However, its efficacy does not match that observed in hematological malignancies. Recently, case series reported targeting CD19 autoimmune diseases such systemic lupus erythematosus, leading to dramatic improvement symptoms possibility discontinuing immunosuppressive agents. Furthermore, expected be effective against viruses Aspergillus spp. Finally, attempts have introduce CAR constructs into regulatory T cells target their effects. This article introduces current progress beyond only discusses future directions, considering medical situation Japan.

Язык: Английский

Процитировано

0